Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

An antibody boost for Servier
May 2020
SHARING OPTIONS:

PARIS & COPENHAGEN, Denmark—Servier and the owners of Symphogen A/S have inked a definitive agreement under which Servier will acquire 100 percent of Symphogen's share capital. Per the agreement, Servier will gain full ownership of Symphogen's oncology and immuno-oncology pipeline as well as its antibody discovery and development platform. Once the transaction is complete, Symphogen will become an antibody center of excellence for Servier's therapeutic areas and will operate as a standalone organization within the Servier group.
 
“This transaction is a key milestone for Symphogen and its owners as it validates the strength of our oncology portfolio and attractiveness of our antibody technologies. Our existing strategic collaboration with Servier has demonstrated the strategic fit between the two organizations, and I am convinced that Servier is well positioned to further enhance the potential of Symphogen,” said Bernhard Ehmer, Symphogen's chairman of the board.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.